Wall Street Zen Upgrades Grifols (NASDAQ:GRFS) to Buy

Grifols (NASDAQ:GRFS) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other research firms also recently issued reports on GRFS. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. decreased their target price on Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a research report on Monday, December 8th. Four analysts have rated the stock with a Hold rating, According to data from MarketBeat, Grifols presently has an average rating of “Hold” and an average price target of $10.00.

Grifols Price Performance

Shares of NASDAQ:GRFS opened at $7.58 on Friday. The company has a current ratio of 2.51, a quick ratio of 0.88 and a debt-to-equity ratio of 1.20. Grifols has a 1 year low of $6.19 and a 1 year high of $11.14. The firm has a fifty day moving average price of $8.92 and a 200 day moving average price of $9.15.

Institutional Trading of Grifols

A number of hedge funds have recently bought and sold shares of GRFS. Bank of Montreal Can increased its holdings in shares of Grifols by 3,205.1% during the 3rd quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after purchasing an additional 2,922,540 shares during the period. Brandes Investment Partners LP raised its position in shares of Grifols by 8.9% during the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock valued at $253,441,000 after buying an additional 2,294,113 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Grifols by 383.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock valued at $27,894,000 after buying an additional 2,221,633 shares during the period. Norges Bank bought a new stake in shares of Grifols in the second quarter valued at about $17,538,000. Finally, Barclays PLC grew its position in Grifols by 132.6% during the fourth quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock worth $22,764,000 after buying an additional 1,387,783 shares in the last quarter.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.